Gilder Gagnon Howe & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-144,476	Closed	-$17.1M	–	298
2022 Q1	$17.1M	Sell	144,476 -114,021	-44%	-$14.2M	0.16%	117
2021 Q4	$35.6M	Buy	258,497 +8,371	+3%	+$1.06M	0.2%	106
2021 Q3	$34.7M	Sell	250,126 -112	-0%	-$14K	0.18%	123
2021 Q2	$24.3M	Sell	250,238 -13,182	-5%	-$1.07M	0.12%	148
2021 Q1	$18M	Buy	263,420 +162,113	+160%	+$13.1M	0.1%	164
2020 Q4	$8.68M	Sell	101,307 -464	-0.5%	-$39.3K	0.04%	193
2020 Q3	$6.62M	Sell	101,771 -581	-0.6%	-$38.1K	0.04%	185
2020 Q2	$7.48M	Buy	102,352 +193	+0.2%	+$10.3K	0.06%	161
2020 Q1	$3.48M	Buy	+102,159	New	+$4.67M	0.04%	157
2017 Q4	–	Sell	-74,637	Closed	-$2.79M	–	318
2017 Q3	$2.79M	Sell	74,637 -2,532	-3%	-$76.8K	0.04%	176
2017 Q2	$1.93M	Buy	+77,169	New	+$1.78M	0.03%	185

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gilder Gagnon Howe & Co's BHVN Position: Q2 2022 in Review

Gilder Gagnon Howe & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 144,476 shares — an estimated $17.1M sold.

Gilder Gagnon Howe & Co first reported a position in BHVN in Q2 2017 and held it in 11 quarters. The position peaked at $35.6M in Q4 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Gilder Gagnon Howe & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 144,476 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $17.1M.
Gilder Gagnon Howe & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 11 quarters.
Gilder Gagnon Howe & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $35.6M in Q4 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2022, filed 15 Aug 2022.